Skip to main content

Table 2 Associations between APOE ε4 genotypes and echocardiographic data in older age by comparing non-APOE ε4 (ε2ε2, ε2ε3, ε2ε3) with APOE ε4 (ε2ε4, ε3ε4 and ε4ε4) genotypes in the meta-analysis pooling SABRE and NSHD data

From: APOE ε4 carriage associates with improved myocardial performance from adolescence to older age

s

 

Model 1

(unadjusted)

Model 2

(adjusted for age, sex, and SEP)

Model 3

(Model 2 + BMI)

Model 4

(Model 2 + CVD)

Model 5

( Model 2 + diabetes)

Model 6

(Model 2 + high cholesterol)

Model 7

(Model 2 + HT)

Outcome

APOE ε4 status

n

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

Exp β (95% CI)

p-value

EF

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

2463 

1.00 (0.98, 1.03)

0.670

1.00 (0.99, 1.02)

0.687

1.00 (0.98, 1.03)

0.677

1.00 (0.99, 1.02)

0.773

1.00 (0.98, 1.02)

0.981

1.01 (0.98, 1.03)

0.689

1.00 (0.98, 1.02)

0.697

E/e’

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

2490 

0.99 (0.96, 1.01)

0.263

0.99 (0.97, 1.02)

0.453

0.99 (0.96, 1.01)

0.274

0.98 (0.96, 1.01)

0.214

0.99 (0.95, 1.03)

0.529

0.98 (0.95, 1.01)

0.116

0.99 (0.96, 1.04)

0.302

LVmass

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

 2230

1.02 (0.98, 1.07)

0.347

1.01 (0.98, 1.04)

0.607

1.03 (0.98, 1.07)

0.258

1.03 (0.97, 1.09)

0.320

1.03 (0.98, 1.09)

0.249

1.02 (0.98, 1.06)

0.294

1.03 (0.98, 1.08)

0.308

MCF

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

2074

1.04 (1.01, 1.07)

0.016

1.04 (1.01, 1.07)

0.008

1.04 (1.01, 1.07)

0.007

1.03 (1.00, 1.06)

0.046

1.03 (1.00, 1.07)

0.069

1.05 (1.00, 1.09)

0.038

1.03 (1.00, 1.06)

0.030

LVPWTs

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

 2476

1.00 (0.97, 1.03)

0.859

0.99 (0.97,1.02)

0.621

1.00 (0.97, 1.03)

0.847

1.00 (0.96, 1.03)

0.907

1.00 (0.97, 1.04)

0.891

1.00 (0.97, 1.03)

0.971

1.00 (0.97, 1.03)

0.882

LVPWTd

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

 2488

1.00 (0.97, 1.04)

0.780

1.00 (0.98, 1.02)

0.967

1.01 (0.97, 1.04)

0.745

1.00 (0.97, 1.04)

0.805

1.01 (0.98, 1.04)

0.710

1.00 (0.98, 1.02)

0.807

1.01 (0.97, 1.04)

0.751

IVSs

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

 2478

1.00 (0.98, 1.01)

0.843

0.99 (0.98, 1.01)

0.480

0.99 (0.98, 1.01)

0.478

1.00 (0.99, 1.02)

0.262

1.00 (0.99, 1.02)

0.881

0.99 (0.98, 1.01)

0.518

1.00 (0.99, 1.02)

0.992

IVSd

No APOE ε4

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

ref

APOE ε4 carriers

 2490

1.00 (0.98, 1.02)

0.776

1.00 (0.98, 1.02)

0.972

1.00 (0.99, 1.02)

0.758

1.00 (0.99, 1.02)

0.644

1.01 (0.99, 1.03)

0.389

1.00 (0.98, 1.03)

0.759

1.00 (0.99, 1.02)

0.605

  1. All reported analyses here consisted of random-effects meta-analyses of coefficients derived from generalized linear models with gamma distribution and log link from both NSHD and SABRE. Significant p-values are highlighted in bold
  2. β Beta regression coefficient, CI Confidence interval, exp Exponentiated, ref Reference. Other abbreviations as in Table 1
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us